Cited In for PMID: 22789508

Year	Number of Results
2012	2
2013	8
2014	6
2015	1
2016	3
2018	1
2019	2
2020	2
2021	2
2022	2
2024	1

1

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults.

Pathan AA, Minassian AM, Sander CR, Rowland R, Porter DW, Poulton ID, Hill AV, Fletcher HA, McShane H. Pathan AA, et al. Vaccine. 2012 Aug 17;30(38):5616-24. doi: 10.1016/j.vaccine.2012.06.084. Epub 2012 Jul 10. Vaccine. 2012. PMID: 22789508 Free PMC article. Clinical Trial.

2

Immunogenicity and protective efficacy of Ag85A and truncation of PstS1 fusion protein vaccines against tuberculosis.

Zeng L, Ma X, Qu M, Tang M, Li H, Lei C, Ji J, Li H. Zeng L, et al. Heliyon. 2024 Feb 23;10(5):e27034. doi: 10.1016/j.heliyon.2024.e27034. eCollection 2024 Mar 15. Heliyon. 2024. PMID: 38463854 Free PMC article.

3

Research Advances for Virus-vectored Tuberculosis Vaccines and Latest Findings on Tuberculosis Vaccine Development.

Hu Z, Lu SH, Lowrie DB, Fan XY. Hu Z, et al. Front Immunol. 2022 Jun 23;13:895020. doi: 10.3389/fimmu.2022.895020. eCollection 2022. Front Immunol. 2022. PMID: 35812383 Free PMC article. Review.

4

An Update on Tuberculosis Vaccines.

Gopalaswamy R, Subbian S. Gopalaswamy R, et al. Methods Mol Biol. 2022;2410:387-409. doi: 10.1007/978-1-0716-1884-4_20. Methods Mol Biol. 2022. PMID: 34914059

5

Phase I Trial Evaluating the Safety and Immunogenicity of Candidate TB Vaccine MVA85A, Delivered by Aerosol to Healthy M.tb-Infected Adults.

Riste M, Marshall JL, Satti I, Harris SA, Wilkie M, Lopez Ramon R, Wright D, Wittenberg RE, Vermaak S, Powell Doherty R, Lawrie A, Conlon CP, Cosgrove C, Gleeson F, Lipman M, Moss P, Perrin F, Dedicoat M, Bettinson H, McShane H. Riste M, et al. Vaccines (Basel). 2021 Apr 16;9(4):396. doi: 10.3390/vaccines9040396. Vaccines (Basel). 2021. PMID: 33923628 Free PMC article.

6

Immunological Considerations for Schistosoma Vaccine Development: Transitioning to Endemic Settings.

Driciru E, Koopman JPR, Cose S, Siddiqui AA, Yazdanbakhsh M, Elliott AM, Roestenberg M. Driciru E, et al. Front Immunol. 2021 Mar 4;12:635985. doi: 10.3389/fimmu.2021.635985. eCollection 2021. Front Immunol. 2021. PMID: 33746974 Free PMC article. Review.

7

The Systematic Review and Meta-Analysis on the Immunogenicity and Safety of the Tuberculosis Subunit Vaccines M72/AS01_E and MVA85A.

Ullah I, Bibi S, Ul Haq I, Safia, Ullah K, Ge L, Shi X, Bin M, Niu H, Tian J, Zhu B. Ullah I, et al. Front Immunol. 2020 Oct 8;11:1806. doi: 10.3389/fimmu.2020.01806. eCollection 2020. Front Immunol. 2020. PMID: 33133057 Free PMC article.

8

Tuberculosis vaccine development: from classic to clinical candidates.

Li J, Zhao A, Tang J, Wang G, Shi Y, Zhan L, Qin C. Li J, et al. Eur J Clin Microbiol Infect Dis. 2020 Aug;39(8):1405-1425. doi: 10.1007/s10096-020-03843-6. Epub 2020 Feb 15. Eur J Clin Microbiol Infect Dis. 2020. PMID: 32060754 Free PMC article. Review.

9

MVA85A vaccine to enhance BCG for preventing tuberculosis.

Kashangura R, Jullien S, Garner P, Johnson S. Kashangura R, et al. Cochrane Database Syst Rev. 2019 Apr 30;4(4):CD012915. doi: 10.1002/14651858.CD012915.pub2. Cochrane Database Syst Rev. 2019. PMID: 31038197 Free PMC article.

10

Novel Modified Vaccinia Virus Ankara Vector Expressing Anti-apoptotic Gene B13R Delays Apoptosis and Enhances Humoral Responses.

Chea LS, Wyatt LS, Gangadhara S, Moss B, Amara RR. Chea LS, et al. J Virol. 2019 Feb 19;93(5):e01648-18. doi: 10.1128/JVI.01648-18. Print 2019 Mar 1. J Virol. 2019. PMID: 30541829 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

28 results

Results by year